Metabolomic Footprints of Lethal Versus Indolent Prostate Cancer
Technical Report,30 Sep 2013,29 Sep 2014
Brigham and Women's Hospital Boston United States
Pagination or Media Count:
The current study proposed to use a targeted, LC-MS-based metabolite profiling platform to measure and compare metabolic profiles of prediagnostic blood samples collected from men subsequently diagnosed with PC and sample of men who remained cancer-free in Physicians Health Study PHS. And test whether these relationships are independent of the known metabolic risk factors overweightobese, insulin marker C-peptide, insulin-like growth factor I IGF-I, IGF binding protein 3, IGFBP-3, and adiponectin as well as the clinical characteristics defined as the DAmico risk. In the original protocol, we plan to measure samples of PC cases from both HPFS and PHS. However, the HPFS team has received separate grant for metabolomics measurement. Therefore, we amended our study population to exclude HPFS data but obtained the HPFS PIs agreement to be able to access to their data for cross validation. Based on the available samples, we utilized matched case control design to select the blood samples to be measured. The selected blood samples are currently being analyzed in the lab and we expect to receive the lab data by early 2015. While we are waiting for the lab results, we have been working on analyzing the related metabolic biomarkers and writing up manuscripts.